AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05271552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Sublingual Placebo Film
Study NCT05277103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exploring predictors of response to a peer-mediated communication intervention for minimally verbal preschoolers with ASD
Description: The intervention, Stay-Play-Talk with iPad, incorporates SGD instruction and peer training, both demonstrated to be effective in increasing communication and social interactions of preschool-age children with ASD. Children with ASD will be provided with an iPad with Touch Chat voice output app (the SGD) to use throughout the project. Two peers are recruited for each child with ASD. Research staff will implement peer training for three 30-min sessions, with peers taught to: STAY - sit close; PLAY- share and take turns; and TALK with iPad - look and listen/push and talk. After peers are trained, they will take turns engaging in common preschool games and preferred play activities with one assigned child with ASD (1 child:1 peer). Treatment will be provided for 15-20 min, twice per week for 8 weeks in the classroom.
Study NCT04955444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality improvement bundle
Description: The quality improvement bundle consists of (1) patient education, (2) provider education, and (3) EHR enhancements including order sets and best practice alerts.
Study NCT05416541 — intervention group
Intervention type: BEHAVIORAL
Intervention: social media
Description: ASA I-II, who speaks and writes Turkish and do not have psychiatric illness patients will attend the study.
Study NCT06261580 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TEG 6s Citrated K, KH, RTH, and FFH Cartridge
Description: The TEG® 6s uses the Global Hemostasis with Heparin Neutralization (HN) Cartridge to test the hemostasis properties of citrated blood samples using four different assays/reagents simultaneously, one in each of the four cartridge channels.
Study NCT06261580 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clauss Fibrinogen
Description: Fibrinogen, also known as Factor I, is a plasma protein that can be transformed by thrombin into a fibrin gel (the clot). Fibrinogen is synthesized in the liver and circulates in the plasma as a disulfide-bonded dimer of 3 subunit chains. The biological half-life of plasma fibrinogen is 3 to 5 days.
Study NCT05687357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: IV infusion
Study NCT05687357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Oral tablets
Study NCT05687357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: Oral tablets
Study NCT05687357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV infusion
Study NCT05687357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: IV infusion
Study NCT05687357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: IV infusion
Study NCT05687357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: IV infusion
Study NCT05687357 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: TOMO/VMAT
Study NCT05687357 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: TOMO/VMAT
Study NCT05399914 — intervention group
Intervention type: OTHER
Intervention: S-NIPPV
Description: Synchronized noninvasive positive pressure ventilation during the first 10 minutes after birth.
Study NCT04550338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Oral administration of blinded medications
Study NCT04550338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of blinded medications
Study NCT05599620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARE
Description: AWARE addresses alcohol use, sexual distress, and sexual assault risk among college women with a history of sexual victimization.
Study NCT05599620 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Health Promotion
Description: General Health Promotion is an attention and dose matched intervention with no overlapping components with AWARE.
Study NCT04886622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT2216
Description: DT2216 will be administered by intravenous infusion
Study NCT06504316 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRRT filter
Description: The subjects will be accepted CRRT using a filter for 72 hours. The subjects will be continued to CRRT or not after 72 hours (the first session of treatment) according to clinical situation by clinician decision. CRRT prescription: 1 Blood purification access: Central vein indwelling double lumen catheter (diameter 11F-13.5F) can be placed in femoral vein, internal jugular vein and subclavian vein; 2.Anti-coagulation prescription: Anticoagulant is used according clinical situation by clinician decision (such as heparin, sodium citrate, and so on); 3. Modality of CRRT: CVVH: blood flow 150-200ml/min; replacement fluid flow 30-35ml/kg/h (100% post-dilution).
Study NCT06504316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRRT filter
Description: The subjects will be accepted CRRT using a filter for 72 hours. The subjects will be continued to CRRT or not after 72 hours (the first session of treatment) according to clinical situation by clinician decision. CRRT prescription: 1 Blood purification access: Central vein indwelling double lumen catheter (diameter 11F-13.5F) can be placed in femoral vein, internal jugular vein and subclavian vein; 2.Anti-coagulation prescription: Anticoagulant is used according clinical situation by clinician decision (such as heparin, sodium citrate, and so on); 3. Modality of CRRT: CVVH: blood flow 150-200ml/min; replacement fluid flow 30-35ml/kg/h (100% post-dilution).
Study NCT06375213 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma tau phosphorylated at Thr217
Description: Plasma concentration of tau protein phosphorylated at Thr217 as measured on the Meso Scale Discovery, single molecule array (Simoa) or the in-house mass spectrometry platform.
Study NCT06375213 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive examination
Description: Traditional (paper and pencil) neurocognitive/neuropsychiatric examination performed by certified psychologists. This includes: Mini Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating (CDR), Wechsler Memory Scale - Fourth Edition (WMS-IV), Neuropsychiatric Inventory - Questionnaire (NPI-Q), Thai Geriatric Depression Scale (TGDS), General Anxiety Disorder - 7 (GAD-7), The Barthel activities of daily living (ADL) Index, Chula ADL Index.
Study NCT04939961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hericium erinaceus
Description: 6 capsules per day, 3 times two after breakfast, lunch and dinner
Study NCT04939961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 capsules per day, 3 times two after breakfast, lunch and dinner
Study NCT05151705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR17031 injection
Description: Treatment group A:HR17031 injection; 10U/0.024mg
Study NCT05151705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR17031 injection
Description: Treatment group B: HR17031 injection; 10U/0.024mg
Study NCT05151705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR17031 injection
Description: Treatment group C: HR17031 injection; 10U/0.024mg
Study NCT05564728 — intervention group
Intervention type: OTHER
Intervention: Conversational Agent/Chatbot App
Description: Well Feet is developed based on adaptive learning frameworks to deliver diabetes foot care education through a conversational agent. The learning path for each participant will be customised based on their responses to pre-module quizzes.
Study NCT04971681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency repetitive transcranial magnetic stimulation (rTMS)
Description: Subjects will receive one session of low frequency repetitive transcranial magnetic stimulation (rTMS) targeting the medial prefrontal cortex (mPFC), within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 110% of motor threshold (MT), for a total of 1200 pulses
Study NCT04971681 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low frequency repetitive transcranial magnetic stimulation (rTMS)
Description: Subjects will receive one session of low frequency repetitive transcranial magnetic stimulation (rTMS) targeting the medial prefrontal cortex (mPFC), within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 110% of motor threshold (MT), for a total of 1200 pulses
Study NCT04971681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
Study NCT04971681 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
Study NCT04989465 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational 23-valent PPV
Description: The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0·5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection
Study NCT04989465 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control 23-valent PPV
Description: The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd. 25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0·5 mL of light disodium phenol phosphate, sodium hydrogen phosphate and sodium chloride per injection
Study NCT06079333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib/trametinib
Description: braf/mek-inhibition
Study NCT05238389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-based upper limb robotic therapy
Description: Patients will be treated using MOTORE, a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints. The intervention will consist of 30 sessions, 1 per day and 5 per week. Therefore, each patient will be treated for 6 weeks~The parameters of the serious games will be proposed by a Decision Support System (DSS), based on an AI-based algorithm trained using data collected during a previous Randomized Controlled Trial.~The DSS will be fed, at the enrollment, with patient's demographics, clinical characteristics, clinical scales and kinematic/kinetic data measured by the robot during an evaluation session (unassisted reaching movements) and updated every 2 sessions with kinematic/kinetic data only, to tailor the treatment to the patient's current abilities.~The therapists will be free to use or not the suggested parameters, on the basis of their previous experience with the robot (over 3 years).
Study NCT05605626 — intervention group
Intervention type: OTHER
Intervention: the better retaining of skills
Description: identify which teaching program has the better retaining of skills
Study NCT05346575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching Obesity Treatments to Adult Learners (TOTAL)
Description: TOTAL includes both video component and motivational telemedicine calls delivered via VA Video Connect (VVC) by a study interventionist. We will invite study participants to watch the 18-minute video at least once. The motivational component of TOTAL will consist of three telemedicine-based (VVC), one-on-one, 30-minute calls at 1 week, 6 months, and 12 months after randomization. This timing was selected so Veterans would have regular interactions with the interventionist within one year of initiating the intervention. Each motivational session will be tailored to where Veterans are in the treatment initiation process. Electronic outcome assessment surveys will be sent to the participants at baseline, at each motivational telemedicine visit, and for the 18 month assessment.
Study NCT05346575 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The usual care group will be electronically sent the 1-week, 6-month, 12-month, 18-month assessments. All usual care participants will be offered the opportunity to watch the educational video component of TOTAL after the final outcome assessment is performed (18 months post-randomization). Veterans in the usual care arm will also have access to the MOVE! program via referrals from the PCP or self-referral to MOVE!. If they initiate treatment in MOVE!, they may progress through MOVE! and receive obesity medications or be referred for bariatric surgery if they choose to do so.
Study NCT05003479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine (Vero Cells), Inactivated
Description: 2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
Study NCT05003479 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
Study NCT05345353 — intervention group
Intervention type: BEHAVIORAL
Intervention: Fat For Fight (FFF), The Aarhus Protocol
Description: A multicomponent family-centered lifestyle intervention which included visits at home and weekly supervised physical activity. Intervention duration - one year maximum
Study NCT05345353 — intervention group
Intervention type: BEHAVIORAL
Intervention: The Children's Obesity Clinic Treatment (TCOCT), The Randers Protocol
Description: A multicomponent family-centered lifestyle intervention which included repeatedly visits (up to 8 times / year). Intervention duration - three years maximum
Study NCT05719649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactic acid bacteria NTU 101
Description: One NTU 101 Lactic Acid Bacteria Vegetable Capsule a day for a total of 12 weeks.~Product ingredients: microcrystalline cellulose, corn starch, NTU 101 Lactobacillus paracasei subsp. paracasei NTU 101 (1.8 x 10\^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
Study NCT05719649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin was used as a placebo
Study NCT04984967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of peripheral venous catheter with micro-guide
Description: After antisepsis, the vein is punctured using a needle. Then the micro-guide is inserted to the first landmark, which indicates the passage of the micro-guide beyond the end of the needle. After the needle removed, the peripheral venous catheter is placed on the micro-guide. The guide is then removed, the peripheral venous catheter can be used.
Study NCT04984967 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Classic insertion of peripheral venous catheter, without micro-guide
Description: After antisepsis, the catheter is introduced into the vein by a needle which is subsequently removed while the catheter remains in place.
Study NCT05555875 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IntelliCare Plus
Description: Mobile-app-based digital mental health intervention for individuals struggling with depression and/or anxiety. The app reflects components of evidence-based psychological treatments such as cognitive-behavioral therapy.
Study NCT05555875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IntelliCare Plus
Description: Mobile-app-based digital mental health intervention for individuals struggling with depression and/or anxiety. The app reflects components of evidence-based psychological treatments such as cognitive-behavioral therapy.
Study NCT06264739 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: esp Dexmedetomidine (dekstomid)
Description: After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (marcaine), 10 ml will consist of lidocaine 2% (aritmal), and 10 ml will consist of physiological saline.
Study NCT06264739 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: esp remifentanyl (ultiva)
Description: After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (marcaine), 10 ml will consist of lidocaine 2% (aritmal), and 10 ml will consist of physiological saline.
Study NCT04958499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bio-healthy Park
Description: Experimental group will receive the exercise program on bio-healthy machinery with a frequency of 2 sessions per week of 55 minutes for 8 weeks. Experimental group 1 will perform the intervention program using machinery designed for self-loading use. The machines used will be rider, low gemini, high gemini, walk, bottoms, flywheels circles, flywheels rotation, twin swing, surf, swing press and rowing. Intensity will be controlled by subjective perception of effort and heart rate (Polar 420). There will be a warm-up 8-10 minutes, a main part 40-45 minutes and a return to calm 5-10 minutes. The intervention programs will be developed by a graduate in Physical Activity and Sport Sciences. The load will be progressed every 2 weeks.
Study NCT06410898 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Punch Biopsy 5mm
Description: Disinfect the skin, inject local anesthesia ,insert the punch and extract the biopsy
Study NCT04781166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm program
Description: 7 online modules designed to teach cognitive behavioral skills
Study NCT04781166 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Calm program
Description: 7 online modules designed to teach cognitive behavioral skills
Study NCT05416866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrolaminar block on the operative side
Description: After the skin near the puncture site was disinfected, 2ml of 1% lidocaine was injected into the puncture site for local infiltration. The needle was inserted beneath the ultrasound probe using an in-plane orientation to contact the lamina of the T8-T11 vertebra. Then we retracted the tip of needle to the lamina about 1 mm and withdrew to make sure that there was no blood or cerebrospinal fluid. Then, 30-40 mL mixture was injected posterior to the lamina of T8-T11.
Study NCT05416866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block on the operative side
Description: In our study, we applied a transmuscular approach to the QLB. After the patients were placed in the lateral position, the skin near the puncture site was disinfected, a low-frequency (3-5 MHz), curvilinear probe is used and is located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. After the local infiltration for puncture site, the 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the QL muscle is confirmed, 30 ml mixture is injected into the interfascial plane.
Study NCT05416866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block on the nonoperative side
Description: After placing the patients in the supine position, the skin was disinfected. A linear probe was placed in the transverse plane at the midaxillary line between the lower costal margin and iliac crest. When the external oblique, internal oblique, and transversus abdominis muscles were observed, 2ml of 1% lidocaine was injected into the puncture site for local infiltration.Then, a 22-gauge, 80-mm needle was advanced using an in-plane technique in an anteromedial to posterolateral direction toward the TAP (the fascial plane between the internal oblique and transversus abdominis muscles). After the correct position of the needle tip was verified, 20 ml mixture was injected into the TAP. The ultrasound showed that the local anesthetic separated the internal oblique and transversus abdominis muscles, confirming the success of the block.
Study NCT05103371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experiment: Millie prevention program, adolescents and active parents
Description: Prevention program: Millie, with the participation of adolescents and parents